Breaking News Instant updates and real-time market news.

KPTI

Karyopharm

$18.50

0.47 (2.61%)

, VYGR

Voyager Therapeutics

$18.11

0.39 (2.20%)

04:55
08/15/18
08/15
04:55
08/15/18
04:55

Wedbush to hold a conference

2018 Wedbush PacGrow Healthcare Conference will be held in New York on August 14-15.

KPTI

Karyopharm

$18.50

0.47 (2.61%)

VYGR

Voyager Therapeutics

$18.11

0.39 (2.20%)

VRNA

Verona Pharma

$13.10

-0.3 (-2.24%)

AVRO

Avrobio

$40.52

-0.08 (-0.20%)

ASND

Ascendis Pharma

$67.70

-0.8 (-1.17%)

OBSV

ObsEva

$12.98

-1.02 (-7.29%)

OMER

Omeros

$20.63

1.45 (7.56%)

NVCR

Novocure

$36.85

-0.1 (-0.27%)

XNCR

Xencor

$40.97

0.28 (0.69%)

PRTK

Paratek Pharmaceuticals

$10.10

0.45 (4.66%)

MGTA

Magenta Therapeutics

$12.99

0.09 (0.70%)

CRVS

Corvus Pharmaceuticals

$9.03

-0.4 (-4.24%)

AKAO

Achaogen

$5.66

-0.165 (-2.84%)

ALBO

Albireo Pharma

$31.77

0.17 (0.54%)

EIGR

Eiger BioPharmaceuticals

$10.05

0.375 (3.88%)

STML

Stemline

$15.40

0.25 (1.65%)

SRRA

Sierra Oncology

$1.95

-0.11 (-5.34%)

ABUS

Arbutus Biopharma

$9.20

-0.45 (-4.66%)

MRSN

Mersana Therapeutics

$12.75

0.04 (0.31%)

SRRK

Scholar Rock

$14.00

0.71 (5.34%)

ARGX

Argenx

$87.50

0.19 (0.22%)

ALNA

Allena Pharmaceuticals

$10.98

0.11 (1.01%)

KURA

Kura Oncology

$19.75

-0.2 (-1.00%)

  • 15

    Aug

  • 15

    Aug

  • 16

    Aug

  • 16

    Aug

  • 19

    Aug

  • 30

    Aug

  • 31

    Aug

  • 04

    Sep

  • 05

    Sep

  • 21

    Feb

KPTI Karyopharm
$18.50

0.47 (2.61%)

05/24/18
WEDB
05/24/18
DOWNGRADE
WEDB
Neutral
Karyopharm downgraded to Neutral from Outperform at Wedbush
05/24/18
05/24/18
DOWNGRADE
Target $19

Neutral
Karyopharm downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst David Nierengarten downgraded Karyopharm to Neutral from Outperform on valuation. The analyst also lowered his price target on the shares to $19 from $20 as he updates his model for the company's offering and for a somewhat shorter duration of therapy based on the STORM duration of response of 4.4 months.
05/24/18
05/24/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jami Rubin citing share outperformance. 2. Petrobras (PBR) downgraded to Equal Weight from Overweight at Morgan Stanley, to Neutral from Outperform at Credit Suisse, to Neutral from Buy at BofA/Merrill, and to Market Perform from Outperform at Itau BBA. 3. Karyopharm (KPTI) downgraded to Neutral from Outperform at Wedbush with analyst David Nierengarten citing valuation. 4. Vermillion (VRML) downgraded to Hold from Buy at Canaccord. 5. Generac (GNRC) downgraded to Neutral from Outperform at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/18
HCWC
05/24/18
NO CHANGE
Target $30
HCWC
Buy
H.C. Wainwright remains bullish Karyopharm after STORM data, license deal
H.C. Wainwright analyst Edward White reiterates a Buy rating and $30 price target for Karyopharm, while pointing out that recent positive Phase 2b STORM data confirmed his expectations for the success of selinexor. The company expects a NDA submission for an accelerated approval of selinexor in patients with penta-refractory multiple myeloma in 2H18, he says, adding that he estimates the addressable peak market size for this population is over $500M in the U.S. The analyst also notes that the company has announced an exclusive license agreement for the development and commercialization of selinexor, eltanexor, verdinexor and KPT-9274 with Antengene Corporation.
VYGR Voyager Therapeutics
$18.11

0.39 (2.20%)

08/09/18
ADAM
08/09/18
NO CHANGE
Target $31
ADAM
Buy
Voyager Therapeutics gene therapy platform under-appreciated, says Canaccord
Canaccord analyst Sumant Kulkarni met with Voyager management and came away noting the company is in the midst of significant management changes. He hopes to see a well-settled management team and if the approval of its pivotal VY-AADC program is successful, it represents a significant opportunity for the company. Kulkarni, who believes its gene-therapy platform is underappreciated by investors, reiterated his Buy rating and $31 price target on Voyager shares.
06/04/18
HCWC
06/04/18
INITIATION
Target $30
HCWC
Buy
Voyager Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Voyager Therapeutics with a Buy rating and $30 price target. The company's VY-AADC is positioned to be a potentially superior alternative to deep brain stimulation, the analyst contends.
06/04/18
06/04/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ventas (VTR) initiated with a Neutral at Cantor Fitzgerald. 2. Voyager Therapeutics (VYGR) initiated with a Buy at H.C. Wainwright. 3. Wyndham Hotels & Resorts (WH) initiated with an Outperform at Oppenheimer as well as a Buy at Goldman Sachs and Stifel. 4. Five Below (FIVE) initiated with an Overweight at JPMorgan. 5. Origin Bancorp (OBNK) was initiated with a Strong Buy at Raymond James and an Overweight at Stephens. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/18
HCWC
06/21/18
NO CHANGE
Target $30
HCWC
Buy
RMAT designation 'a nice to have' for Voyager, says H.C. Wainwright
After Voyager Therapeutics reported that the FDA granted Regenerative Medicine Advanced Therapy designation for the company's VY-AADC gene therapy treatment for Parkinson's disease, H.C. Wainwright analyst Debjit Chattopadhyay called the designation a "nice to have" that provides greater regulatory interactions and potential for expedited review. RMAT "does not and should not lower the standards of approval," however, said Chattopadhyay, who maintains his existing probability of success scenarios. He keeps a Buy rating and $30 price target on Voyager shares.
VRNA Verona Pharma
$13.10

-0.3 (-2.24%)

03/27/18
RHCO
03/27/18
NO CHANGE
Target $37
RHCO
Buy
Verona Pharma price target raised to $37 from $26 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Verona Pharma to $37 after the company's "highly favorable" phase 2b results for RPL 554 in COPD maintenance. The analyst raises his probability of success on the treatment to 40% from 33% and adjusts his model based on the data while also keeping his Buy rating on Verona Pharma.
02/20/18
BREN
02/20/18
INITIATION
Target $30
BREN
Buy
Verona Pharma initiated with a Buy at Berenberg
Berenberg analyst Patrick Trucchio initiated Verona Pharma with a Buy and $30 price target.
03/27/18
WEDB
03/27/18
NO CHANGE
Target $55
WEDB
Outperform
Verona Pharma price target raised to $55 from $48 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Verona Pharma to $55 from $48 as statistically significant, clinically meaningful Phase 2b results for nebulized RPL554 maintenance therapy of COPD reinforce the clinical benefits of dual PDE3/PDE4 inhibition in respiratory diseases. The analyst reiterates an Outperform rating on the shares.
AVRO Avrobio
$40.52

-0.08 (-0.20%)

07/16/18
WEDB
07/16/18
INITIATION
Target $38
WEDB
Outperform
AvroBio initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten started AvroBio with an Outperform rating and $38 price target as he believes the shares could have significant upside given that its gene therapy platform is developing potentially curative therapies for rare lysosomal storage diseases that are poorly controlled on current treatments.
07/16/18
MSCO
07/16/18
INITIATION
Target $37
MSCO
Overweight
AvroBio initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz initiated AvroBio (AVRO) with an Overweight rating and $37 price target, noting that its a unique gene therapy company that has human clinical data for one of its programs at the time of its initial public offering. He points to Novartis' (NVS) recent acquisition of AveXis for $8.7B, or an 88% premium, as an illustration of the substantial interest in and valuation premium put into many names in the gene therapy space.
07/16/18
COWN
07/16/18
INITIATION
COWN
Outperform
AvroBio initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated AvroBio with an Outperform rating citing its four programs that have been generated from its lentiviral gene therapy platform for lysomal storage diseases. The analyst expects the company to create long-term value with its gene therapy programs.
07/16/18
WELS
07/16/18
INITIATION
Target $40
WELS
Outperform
AvroBio initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started AvroBio with an Outperform rating and $40 price target based on what he views as a differentiated capability in applying lentiviral-based gene therapy, a proven platform with curative potential, to lysosomal storage diseases, proof-of-mechanism afforded by existing LSD treatment approaches including enzyme replacement therapy and allogeneic hematopoietic stem cell transplant, encouraging initial phase 1 data in Fabry disease demonstrating rapid, robust, and sustained enzyme expression, and a leverageable platform that extends to multiple LSDs with established markets and multibillion dollar opportunities.
ASND Ascendis Pharma
$67.70

-0.8 (-1.17%)

05/14/18
JPMS
05/14/18
NO CHANGE
Target $79
JPMS
Overweight
Ascendis Pharma added to Analyst Focus List at JPMorgan
JPMorgan analyst Jessica Fye added Ascendis Pharma to the firm's Analyst Focus List, citing confidence in the company's "consistent clinical and preclinical data" across its orphan endocrinology pipeline. Fye sees Ascendis transitioning from being viewed as a single product company to one with multiple orphan endocrine assets in the clinic and a platform story. The analyst, who sees a high probability of success for the company's lead asset TransCon hGH, reiterates her Overweight rating and raised her price target on Ascendis shares to $79 from $75.
03/21/18
JPMS
03/21/18
NO CHANGE
Target $75
JPMS
Overweight
Ascendis Pharma price target raised to $75 from $60 at JPMorgan
JPMorgan analyst Jessica Fye raised her price target for Ascendis Pharma to $75 saying she remains "very positive" following the company's ENDO 2018 data presentations for both the TransCon hGH and PTH programs. The analyst believes Ascendis is in the midst of a transformation to a company with multiple orphan endocrine assets in human testing, and ultimately a platform story. She sees a high probability of success for the Phase III trial evaluating TransCon Growth Hormone for pediatric growth hormone deficiency. Fye keeps an Overweight rating on Ascendis Pharma.
05/31/18
LEER
05/31/18
NO CHANGE
Target $70
LEER
Market Perform
Ascendis Pharma price target raised to $70 from $64 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Ascendis Pharma to $70 from $64 following quarterly results. The analyst reiterates a Market Perform rating on the shares.
06/26/18
STFL
06/26/18
INITIATION
Target $85
STFL
Buy
Ascendis Pharma initiated with a Buy at Stifel
Stifel analyst Adam Walsh initiated Ascendis Pharma with a Buy rating and $85 price target, stating that he sees the company's TransCon technology having "game-changing" potential to fix the pharmacokinetic and related clinical shortcomings of both currently approved drugs as well as those in development.
OBSV ObsEva
$12.98

-1.02 (-7.29%)

08/07/18
08/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Broadcom (AVGO) reinstated with an Overweight at Barclays. 2. ObsEva (OBSV) initiated with an Outperform at Wedbush. 3. Deciphera (DCPH) initiated with a Buy at Canaccord. 4. Alliance Data (ADS) assumed with a Buy at Jefferies. 5. Hermes (HESAY) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/18
HCWC
08/08/18
NO CHANGE
Target $44
HCWC
Buy
ObsEva price target raised to $44 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ObsEva (OBSV) to $44 based on the disclosed pricing for AbbVie's (ABBV) Orilissa, the fgonadotropin-releasing hormone receptor antagonist for endometriosis and uterine fibroids. ObsEva management had previously guided to the cost of GnRH receptor antagonist therapy at $15 per day, about $450 per month, and the proposed monthly cost of Orilissa at $845 "appears to be comfortably above this level," Selvaraju tells investors in a research note. As such, the analyst elected to revise his pricing assumptions upward for ObsEva's linzagolix to reflect a daily cost of $25. He keeps a Buy rating on ObsEva shares.
08/06/18
WEDB
08/06/18
INITIATION
WEDB
Outperform
ObsEva initiated with an Outperform at Wedbush
08/07/18
WEDB
08/07/18
INITIATION
Target $34
WEDB
Outperform
ObsEva initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started ObsEva with an Outperform rating and $34 price target. The analyst projects initial approvals/launches in the U.S. and EU in 2021-2022, full-year profitability in 2024 and the potential to reach over $1B in total revenues in 2026.
OMER Omeros
$20.63

1.45 (7.56%)

07/12/18
GHSC
07/12/18
INITIATION
Target $30
GHSC
Buy
Omeros initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Omeros with a Buy and $30 price target saying Omidria for cataract surgery regains pass-through starting October 1 following new legislation. Davis expects the company to quickly return to an annualized run-rate of $87M, and if it secures permanent reimbursement from CMS, likely $200M-$400M in peak sales.
03/23/18
WEDB
03/23/18
DOWNGRADE
Target $19
WEDB
Neutral
Omeros downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Liana Moussatos downgraded Omeros to Neutral and lowered her price target for the shares to $19 from $47. The analyst sees a "lack of clarity for the financial status" with disruption in Omidria sales and the company's inability to fund progress with its top potential value driver OMS721. Even with possible extension of Omidria pass-through reimbursement for two additional years starting in October 2018, sales are unlikely to fund the pipeline in 2018 and 2019, Moussatos tells investors in a research note. Omeros closed yesterday up 35%, or $4.11, to $15.75.
03/22/18
MAXM
03/22/18
NO CHANGE
Target $25
MAXM
Buy
Omeros short-term reimbursement overhang removal 'great news,' says Maxim
Maxim analyst Jason McCarthy said Omeros resolution of of reimbursement "pass through" status removes an overhang. McCarthy expects Omidria to return to its previous trend of growing sales, and raised his estimates for 2018 to account for the news, while increasing his price target to $25 from $24 and reiterating a Buy rating on Omeros shares
03/23/18
HCWC
03/23/18
NO CHANGE
Target $34
HCWC
Buy
Omeros price target raised to $34 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Omeros to $34 after Omidria pass-through reimbursement status was extended. The language in the spending bill provides the extension for a period of two years, Selvaraju tells investors in a research note. This is an "unexpected success" for Omeros, and should lead to a "significant rebound" in Omidria sales and resumption of growth in the franchise, Selvaraju writes. He reiterates a Buy rating on Omeros shares.
NVCR Novocure
$36.85

-0.1 (-0.27%)

07/25/18
DBAB
07/25/18
DOWNGRADE
DBAB
Hold
Novocure downgraded to Hold from Buy at Deutsche Bank
04/19/18
DBAB
04/19/18
UPGRADE
Target $29
DBAB
Buy
Novocure upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert upgraded Novocure to Buy and raised his price target for the shares to $29 from $19. The analyst says Novocure remains an "under-the-radar oncology story." Following the positive Phase 2 results in mesothelioma, the analyst now assumes a near-term filing and year-end FDA approval of Optune. An approval in the smaller indication could make investors consider Optuneb's potential in the much larger lung and pancreatic cancer setting, Gilbert tells investors in a research note. He sees investor interest in Novocure growing.
07/16/18
EVER
07/16/18
INITIATION
Target $46
EVER
Outperform
Novocure initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar initiated Novocure with an Outperform and $46 price target. Kumra believes Novocure is at an inflection point with the full data-set of mesothelioma expected in 2H 2018 and sees a potential big catalyst in 2019 with receipt of reimbursement from CMS.
07/25/18
DBAB
07/25/18
DOWNGRADE
Target $31
DBAB
Hold
Novocure downgraded to Hold on valuation at Deutsche Bank
Deutsche Bank analyst Gregg Gilbert downgraded Novocure to Hold from Buy with an unchanged price target of $31. The analyst cites valuation for the downgrade but says he remains bullish on the name over the long term.
XNCR Xencor
$40.97

0.28 (0.69%)

06/06/18
BTIG
06/06/18
INITIATION
Target $56
BTIG
Buy
Xencor initiated with a Buy at BTIG
BTIG analyst Dane Leone started Xencor with a Buy rating and $56 price target. The analyst is optimistic for the use of XmAb5871 in the treatment of systemic lupus erythematosus into the Phase 2 read-out during the second half of 2018. Further, he believes the commercialization of Xencor's partner assets, ALXN1210 and MOR208, should help support its cash flow for the next several years.
06/07/18
06/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Xencor (XNCR) initiated with a Buy at BTIG. 2. Donnelley Financial Solutions (DFIN) initiated with a Buy at DA Davidson. 3. Axsome Therapeutics (AXSM) initiated with a Buy at H.C. Wainwright. 4. ShotSpotter (SSTI) initiated with an Outperform at JMP Securities. 5. WellCare (WCG) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/07/18
PIPR
08/07/18
NO CHANGE
Target $52
PIPR
Overweight
Xencor price target raised to $52 from $46 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Xencor to $52 following the company's Q2 results. The company remains a top pick for its bispecific antibody and cytokine pipeline to treat cancer, Tenthoff tells investors in a research note. He notes Xencor has $555M of cash and reiterates an Overweight rating on the shares.
08/08/18
ADAM
08/08/18
NO CHANGE
Target $45
ADAM
Buy
Xencor price target raised to $45 from $38 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Xencor to $45 from $38 noting the clinical data for the company's first bi-specific, XmAb, is on track for 2018. She said there are four other bi-specifics that are complete, giving it a pipeline that is very attractive. Lee reiterated her Buy rating on Xencor shares.
PRTK Paratek Pharmaceuticals
$10.10

0.45 (4.66%)

04/06/18
CANT
04/06/18
NO CHANGE
Target $50
CANT
Overweight
Paratek Pharmaceuticals shares remain undervalued, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen said yesterday afternoon that shares of Paratek Pharmaceuticals remain undervalued with potential approval of omadacycline and Seysara. The FDA's acceptance of the company's omadacycline new drug application for priority review is in line with expectations, Chen tells investors in a research note. She keeps an Overweight rating on the shares with a $50 price target.
08/09/18
WEDB
08/09/18
NO CHANGE
Target $20
WEDB
Tone of Paratek advisory committee meeting 'extremely positive,' says Wedbush
Wedbush analyst Robert Driscoll said the tone of yesterday's antimicrobials drug advisory committee meeting was "extremely positive" regarding to the data presented by Paratek and he expects full approval of omadacycline for the treatment of both acute bacterial skin infections and community-acquired bacterial pneumonia in early October. He believes the flexible dosing, low risk of C. difficile and lack of drug-drug interactions will support significant commercial success of omadacycline. Driscoll keeps an Outperform rating and $20 price target on Paratek shares.
08/06/18
HCWC
08/06/18
NO CHANGE
Target $55
HCWC
Buy
Paratek risk/reward favorable into Wednesday's panel, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce believes the risk/reward for Paratek Pharmaceuticals is "positively-skewed" into Wednesday's FDA panel meeting for omadacycline. The analyst expects a "relatively smooth" panel and would be buyers of the stock heading into the early October FDA action date. Arce keeps a Buy rating on Paratek with a $55 price target.
08/08/18
RAJA
08/08/18
NO CHANGE
RAJA
Outperform
AdCom vote increases chances of Paratek's omadacycline approval, says Raymond James
Raymond James analyst Laura Chico notes that the FDA's Advisory Committee voted 17-1 in favor of approval for Paratek Pharmaceuticals' omadacycline in skin infections and 14-4 in favor of approval in pneumonia. While the analyst acknowledges that the FDA is not bound by the committee's decision, they nearly always follow the recommendation. Thus, she thinks the vote incrementally increases the chances for an omadacycline approval. Chico reiterates an Outperform rating on the shares.
MGTA Magenta Therapeutics
$12.99

0.09 (0.70%)

07/16/18
COWN
07/16/18
INITIATION
COWN
Outperform
Magenta Therapeutics initiated with an Outperform at Cowen
Cowen analyst Marc Frahm initiated Magenta Therapeutics with an Outperform rating as he believes the company's drug pipeline candidates have the potential to improve several aspects of a stem cell transplant and could transform the accessibility of transplantation. Frahm expects Magenta Therapeutics shares to appreciate as multiple candidates advance in development.
07/16/18
GSCO
07/16/18
INITIATION
Target $18
GSCO
Buy
Magenta Therapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Magenta Therapeutics with a Buy rating and $18 price target. The company's focus on transplant is compelling with new data expected from three programs in the second half of 2018, Flynn tells investors in a research note.
07/16/18
WEDB
07/16/18
INITIATION
Target $22
WEDB
Outperform
Magenta Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten started Magenta Therapeutics with an Outperform rating and $22 price target, noting that the company is developing its wholly-owned pipeline of therapies that aim to improve every major step of the hematopoietic stem cell transplant process, providing multiple shots on goal in an area largely overlooked by drug developers.
07/16/18
JPMS
07/16/18
INITIATION
Target $18
JPMS
Overweight
Magenta Therapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye started Magenta Therapeutics with an Overweight rating and $18 price target. The analyst believes the company is positioned to transform the stem cell transplant market.
CRVS Corvus Pharmaceuticals
$9.03

-0.4 (-4.24%)

08/23/17
FBCO
08/23/17
UPGRADE
FBCO
Neutral
Corvus Pharmaceuticals upgraded to Neutral from Underperform at Credit Suisse
06/05/18
JEFF
06/05/18
INITIATION
Target $17
JEFF
Buy
Corvus Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Corvus Pharmaceuticals with a Buy rating and $17 price target. The analyst views CPI-444 as a potentially interesting immuno-oncology asset in non-small cell lung cancer and renal cell carcinoma.
08/24/17
FBCO
08/24/17
UPGRADE
Target $14
FBCO
Neutral
Corvus Pharmaceuticals upgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Corvus Pharmaceuticals to Neutral from Underperform ahead of additional data expected at SITC in November. The analyst also raised his price target to $14 from $12.
AKAO Achaogen
$5.66

-0.165 (-2.84%)

08/07/18
NEED
08/07/18
DOWNGRADE
NEED
Hold
Achaogen downgraded to Hold at Needham on drug program risk
As noted earlier, Needham anayst Alan Carr downgraded Achaogen to Hold from Buy after its quarterly update, saying that while he sees the company's Zemdri antibiotic to be most relevant in the CRE market, he sees it as "modest in size and at high risk of becoming crowded". Carr adds that the other potential major product for the company such as C-Scape is at higher risk with a longer commercialization time frame then previously expected. The analyst also notes Achaogen's cash position of $100.5M, which is only sufficient to sustain operations through Q1 of 2019.
08/07/18
NEED
08/07/18
DOWNGRADE
NEED
Hold
Achaogen downgraded to Hold from Buy at Needham
07/13/18
WBLR
07/13/18
NO CHANGE
WBLR
Outperform
Achaogen 30% pullback since last month overdone, says William Blair
After attending the company's investor event, William Blair analyst Y. Katherine Xu says shares of Achaogen at current levels offer an attractive entry opportunity. While most of the Street has modeled the use of Zemdri in carbapenem-resistant enterobacteriaceae, extended-spectrum beta-lactamases-producing bacteria is also a major target and represents a much larger population, Xu tells investors in a research note. Further, she believes physicians are and will be comfortable to use Zemdri off-label in blood stream infections and pneumonia. The analyst views the 30% pullback in Achaogen shares since the complicated urinary tract infections approval last month as overdone and thinks her $23 fair value estimate could prove conservative. Xu keeps an Outperform rating on Achaogen.
08/03/18
08/03/18
NO CHANGE

Achaogen's Zemdri granted NTAP status by the CMS
Achaogen announced that the Centers for Medicare & Medicaid Services - CMS - has granted a new technology add-on payment, or NTAP, for Zemdri when administered in the hospital inpatient setting. The NTAP program will provide hospitals with a payment, in addition to the standard-of-care Diagnostic Related Group reimbursement, of up to 50% of the cost of Zemdr ifor a period of two to three years, effective in the 2019 fiscal year starting on October 1, 2018. CMS has assigned a maximum payment of $2,722.50 for a patient treated with ZEMDRI.
ALBO Albireo Pharma
$31.77

0.17 (0.54%)

02/02/18
NEED
02/02/18
NO CHANGE
Target $50
NEED
Buy
Albireo Pharma price target raised to $50 from $35 at Needham
Needham analyst Alan Carr raised his price target on Albireo Pharma to $50 and kept his Buy rating, revising his model to reflect the new elobixibat royalty agreement and subsequent regulatory approval of the drug in Japan for Chronic Constipation. The analyst adds he is "favorably inclined" toward results expected to be released around 2019-end based on the Phase 2 data of the drug.
04/20/18
JEFF
04/20/18
INITIATION
Target $50
JEFF
Buy
Albireo Pharma initiated with a Buy at Jefferies
Jefferies analyst Eun Yang starts Albireo Pharma with a Buy rating and $50 price target. The company is a "relatively under-recognized story," but has an attractive Phase 3 pediatric orphan liver disease product, designed to address a real unmet need, Yang tells investors in a research note. She thinks appreciation in the shares is likely ahead of the Phase 3 lead product data towards the end of 2019.
04/20/18
04/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Roku (ROKU) initiated with a Hold at Loop Capital. 2. Merit Medical (MMSI) initiated with a Buy at Needham. 3. Wingstop (WING) initiated with a Buy at BTIG. 4. Globant (GLOB) initiated with a Hold at HSBC. 5. Albireo Pharma (ALBO) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/17
11/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Albireo Pharma (ALBO) initiated with a Buy at Roth Capital. 2. Qudian (QD) was initiated with a Buy at Stifel and an Equal Weight at Morgan Stanley. 3. Platform Specialty Products (PAH) reinitiated with a Neutral at Credit Suisse. 4. Karyopharm (KPTI) assumed with a Buy at H.C. Wainwright. 5. Extraction Oil & Gas (XOG) initiated with an Outperform at Imperial Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
EIGR Eiger BioPharmaceuticals
$10.05

0.375 (3.88%)

05/30/18
PIPR
05/30/18
NO CHANGE
Target $24
PIPR
Overweight
Eiger BioPharmaceuticals price target lowered to $24 from $28 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Eiger BioPharmaceuticals to $24 to account for dilution from the recent financing. The analyst expects Phase II readouts for exendin in hypoglycemia and ubenimex in lymphedema in Q3. He reiterates an Overweight rating on the shares.
05/09/18
05/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cleveland-Cliffs (CLF) initiated with a Buy at Seaport Global. 2. Amneal Pharmaceuticals (AMRX) initiated with a Buy at Deutsche Bank. 3. Iridium (IRDM) initiated with a Buy at BWS Financial. 4. ServiceMaster (SERV) initiated with a Buy at Buckingham while Rollins (ROL) was initiated with a Neutral at Buckingham. 5. Eiger BioPharmaceuticals (EIGR) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/18/18
PIPR
05/18/18
NO CHANGE
Target $28
PIPR
Overweight
Eiger BioPharmaceuticals price target raised to $28 from $17 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Eiger BioPharmaceuticals (EIGR) to $28 after the company expanded its lonafarnib licensing agreement with Merck (MRK) for rights in ultra-orphan indication Hutchinson-Gilford Progeria syndrome. The analyst now anticipates FDA approval of lonafarnib in HGPS in 2020. He reiterates an Overweight rating on Eiger shares.
05/17/18
WEDB
05/17/18
NO CHANGE
Target $53
WEDB
Outperform
Eiger BioPharmaceuticals price target raised to $53 from $36 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Eiger BioPharmaceuticals (EIGR) to $53 from $36 after the company expanded its licensing agreement with Merck (MRK) to include Hutchinson-Gilford Progeria Syndrome, or progeria, a fatal premature aging disease for which there are no approved drugs, after publication on April 24 in the Journal of the American Medical Association of Phase 2 results demonstrating a survival benefit -- after 2.2 years, only 1 of 27 lonafarnib-treated progeria syndrome patients died compared to 9 of 27 of untreated patients. In a research note to investors, Moussatos, who has an Outperform rating on shares, said that Eiger now has worldwide rights for progeria, HDV and all lonafarnib indications is a "game-changer" for the company.
STML Stemline
$15.40

0.25 (1.65%)

06/12/18
ROTH
06/12/18
INITIATION
Target $30
ROTH
Buy
Stemline initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Stemline with a Buy rating and $30 price target, stating that he expects the company to "sail smoothly through a BLA and then through M&A," given the strengths he sees for its lead asset SL-401, which is being investigated for an indication with no standard of care - front-line, blastic plasmacytoid dendritic cell neoplasm, or BPDCN.
05/01/18
HCWC
05/01/18
NO CHANGE
Target $38
HCWC
Buy
H.C. Wainwright reiterates Buy on Stemline after Karyopharm data
Karyopharm Therapeutics' (KPTI) positive data last night for selinexor in multiple myeloma validates the mechanism of XPO1 inhibition, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. As such, the analyst is "cautiously optimistic" about the potential of Stemline Therapeutics' (STML) SL-801 for the treatment of cancers. SL-801 is an oral small molecule inhibitor of XPO1 and is being investigated in a Phase 1 trial in patients with advanced solid tumors, Selvaraju points out. He notes SL-801 is currently excluded in his $38 price target for Stemline. Selvaraju reiterates a Buy rating on the shares.
SRRA Sierra Oncology
$1.95

-0.11 (-5.34%)

06/15/18
06/15/18
NO CHANGE

Sierra Oncology files $200M mixed securities shelf
10/23/17
JEFF
10/23/17
UPGRADE
Target $4
JEFF
Buy
Sierra Oncology upgraded to Buy from Hold at Jefferies
Jefferies analyst Maury Raycroft upgraded Sierra Oncology to Buy and raised his price target for the shares to $4.00 from $1.50. The company is "rapidly advancing" SRA737 through dose-escalation in two clinical studies and the program is "under-the-radar," Raycroft tells investors in a research note. He believes Sierra's clinical strategy is "differentiated and innovative" and recommends buying the shares ahead of the Q1 of 2018 data.
ABUS Arbutus Biopharma
$9.20

-0.45 (-4.66%)

03/19/18
CHDN
03/19/18
INITIATION
Target $8.25
CHDN
Buy
Arbutus Biopharma reinitiated with a Buy at Chardan
Chardan analyst Gbola Amusa resumed coverage on Arbutus Biopharma with a Buy and $8.25 price target.
03/19/18
03/19/18
DOWNGRADE
Target $6

Neutral
Arbutus Biopharma downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst Robert Driscoll downgraded Arbutus Biopharma to Neutral from Outperform as he sees limited upside to shares ahead of a lack of meaningful catalysts over the next 12 months. The analyst also lowered his price target on the shares to $6 from $9.
07/06/18
RILY
07/06/18
DOWNGRADE
Target $9
RILY
Neutral
Arbutus Biopharma downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar downgraded Arbutus Biopharma to Neutral with an unchanged price target of $9. The analyst cites valuation for the downgrade following the stock's recent rally.
07/06/18
07/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Arbutus Biopharma (ABUS) downgraded to Neutral from Buy at B. Riley FBR with analyst Madhu Kumar citing valuation following the stock's recent rally. 2. Gannett (GCI) downgraded to Underweight from Neutral at JPMorgan with analyst Alexia Quadrani saying she expects ongoing secular concerns in the print marketplace to bring further volatility. 3. L'Oreal (LRLCY) downgraded to Hold from Buy at Deutsche Bank with analyst Eva Quiroga stating that following the stock's outperformance, she sees "limited incremental upside at best" from current share levels. 4. Carnival (CCL) downgraded to Hold from Buy at Argus with analyst John Staszak saying the company is faced with near-term challenges such as more difficult prior-year comparisons, soft advance bookings, higher fuel costs, and adverse FX rates. 5. Preferred Bank (PFBC) downgraded to Equal Weight from Overweight at Stephens with analyst Tyler Stafford citing valuation, noting that the stock now trades in-line with its peer group. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRSN Mersana Therapeutics
$12.75

0.04 (0.31%)

05/08/18
05/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Juniper (JNPR) initiated with a Neutral at Rosenblatt. 2. Nice Systems (NICE) initiated with an Equal Weight at Morgan Stanley. 3. Mersana Therapeutics (MRSN) initiated with an Outperform at Baird. 4. iQIYI (IQ) initiated with a Buy at Goldman Sachs. 5. Cubic (CUB) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/07/18
BARD
05/07/18
INITIATION
Target $30
BARD
Outperform
Mersana Therapeutics initiated with an Outperform at Baird
Baird initiated Mersana Therapeutics with an Outperform and $30 price target.
07/20/18
HCWC
07/20/18
NO CHANGE
Target $16
HCWC
Buy
Mersana Therapeutics price target lowered to $16 from $33 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Mersana Therapeutics to $16 after the company disclosed a partial clinical hold on its lead clinical program targeting HER2 expressing cancers. Unfortunately, the setback delays progress in a very competitive segment, Chattopadhyay tells investors in a research note. Despite the issues with XMT-1522, the analyst is "holding out hope" for the DolaFlexin platform. He keeps a Buy rating on Mersana Therapeutics.
07/19/18
LEER
07/19/18
DOWNGRADE
LEER
Market Perform
Mersana Therapeutics downgraded to Market Perform from Outperform at Leerink
SRRK Scholar Rock
$14.00

0.71 (5.34%)

06/18/18
WEDB
06/18/18
INITIATION
Target $25
WEDB
Outperform
Scholar Rock initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten started Scholar Rock with an Outperform rating and $25 price target saying it is taking a unique approach to inhibiting TGF beta, a key class of interest for drug developers but one considered too difficult to drug with specificity, by locking the proteins in their latent state. This strategy, and supportive preclinical data, give him confidence that the company's programs could be the first to safely shut down TGF beta signaling in a targeted manner, with application in several serious disorders.
06/18/18
JEFF
06/18/18
INITIATION
Target $26
JEFF
Buy
Scholar Rock initiated with a Buy at Jefferies
Jefferies analyst Michael Yee started Scholar Rock with a Buy rating and $26 price target. Similar to other orphan drug stories, early data could offer 50%-plus upside into 2019 if they show early benefit in spinal muscular atrophy patients, Yee tells investors in a research note.
06/18/18
BMOC
06/18/18
INITIATION
Target $31
BMOC
Outperform
Scholar Rock initiated with an Outperform at BMO Capital
BMO Capital analyst Do Kim initiated Scholar Rock with an Outperform rating and a price target of $31, citing his expectations of its proprietary research platform answering the challenges of modulating transforming growth factor beta signaling pathways. The analyst adds that the company's SRK-015 program has "properly aligned the drug's specific benefit to an ideal disease setting" and expects the Phase 1 data in Q4 to confirm its safety and PK/PD profile, with eventual proof-of-concept data coming in the second half of 2019.
06/18/18
COWN
06/18/18
INITIATION
Target $18
COWN
Outperform
Scholar Rock initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated Scholar Rock with an Outperform rating as she believes its lead product, SRK-015, which is a myostatin activation inhibitor in development for SMA type 2 and 3, has significant clinical promise with peak potential U.S. sales of $1.6B. Baral has an $18 price target on Scholar Rock shares.
ARGX Argenx
$87.50

0.19 (0.22%)

06/18/18
JMPS
06/18/18
NO CHANGE
Target $130
JMPS
Outperform
Argenx price target raised to $130 from $93 at JMP Securities
JMP Securities analyst Jason Butler increased his price target on Argenx to $130 from $93, stating that he believes there is "clear agreement" with the FDA that a single pivotal trial for efgartigimod to treat generalized myasthenia gravis confirming the Phase 2 results will support approval. He is also anticipating positive results from efgartigimod Phase 2 trials in immune thrombocytopenia and pemphigus vulgaris, Butler tells investors.
06/29/18
NOMU
06/29/18
INITIATION
Target $161
NOMU
Buy
Argenx initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Christopher Marai started Argenx with a Buy rating and $161 price target. The analyst sees several catalysts over the next 12 months that he believes will de-risk multiple Phase 3 trials of lead drug efgartigimod, an antibody fragment targeting the FcRn receptor for the treatment of antibody-mediated disease. Marai recommends owning the shares.
06/25/18
WEDB
06/25/18
NO CHANGE
Target $114
WEDB
Outperform
Argenx price target raised to $114 from $93 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Argenx to $114 from $93 given the topline data from the Phase 2 study of efgartigimod in pemphigus vulgaris demonstrating rapid disease control and strong PD effect in the first cohort of patients and a further review of the ITP market opportunity. The analyst reiterates an Outperform rating on the shares.
06/19/18
PIPR
06/19/18
NO CHANGE
Target $130
PIPR
Overweight
Argenx's phase 2 efgartigimod ITP data expected in September, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Argenx is conducting a Phase II study of efgartigimod in 36 immune thrombocytopenia patients with data expected in September. The company is also conducting an open-label Phase II study of efgartigimod in pemphigus vulgaris with data from the first 4 patients near-term, and plans to initiate a single Phase III trial of efgartigimod in generalized myasthenia gravis this year. Pointing out that a recent KOL event highlighted unmet medical need in ITP, Tenthoff reiterates an Overweight rating and $130 price target on Argenx shares.
ALNA Allena Pharmaceuticals
$10.98

0.11 (1.01%)

04/02/18
ROTH
04/02/18
INITIATION
Target $61
ROTH
Buy
Allena Pharmaceuticals initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started Allena Pharmaceuticals with a Buy rating and $61 price target, contending that the company is a "leading pioneer" in the space of enteric hyperoxaluria, where there is a minimal competitive landscape and the company has a Phase 3 asset in ALLN-177. Rahimi makes the case that Allena is significantly undervalued, partly due to a lack of disease awareness.
04/25/18
RILY
04/25/18
INITIATION
Target $23.5
RILY
Buy
Allena Pharmaceuticals initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Allena Pharmaceuticals with a Buy rating and $23.50 price target. The analyst sees a favorable risk/reward profile into the Phase III results for ALLN-177 in patients with enteric hyperoxaluria.
08/02/18
LTCO
08/02/18
INITIATION
Target $23
LTCO
Buy
Allena Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan started Allena Pharmaceuticals with a Buy rating and $23 price target.
08/02/18
08/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Magnolia Oil & Gas (MGY) initiated with a Buy at SunTrust. 2. VICI Properties (VICI) initiated with a Neutral at Citi. 3. Cision (CISN) initiated with a Buy at Citi. 4. Allena Pharmaceuticals (ALNA) initiated with a Buy at Ladenburg. 5. NXP Semiconductors (NXPI) reinstated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
KURA Kura Oncology
$19.75

-0.2 (-1.00%)

02/16/18
OPCO
02/16/18
NO CHANGE
Target $30
OPCO
Outperform
Kura Oncology price target raised to $30 from $17.50 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Kura Oncology to $30 citing the positive updated preliminary results from the company's Phase II study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma. The analyst increased her estimated revenue in 2020-2022 by 66.7% per year. She keeps an Outperform rating on Kura Oncology.
02/16/18
SBSH
02/16/18
NO CHANGE
Target $28
SBSH
Buy
Kura Oncology price target raised to $28 from $19 at Citi
Citi analyst Joel Beatty raised his price target for Kura Oncology to $28 citing increased confidence that Tipifarnib is a differentiated therapy for the treatment of HRAS mutant head and neck squamous cell cancer. The analyst sees a 55% probability of success. It is more probable than not that the five of eight, or 63% response rate observed thus far in head and neck squamous cell cancer is a "real efficacy signal," and the duration of response in this indication reinforces this view, Beatty tells investors in a research note. The analyst keeps a Buy rating on Kura Oncology.
08/01/18
HCWC
08/01/18
INITIATION
Target $31
HCWC
Buy
Kura Oncology initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Kura Oncology with a Buy rating and $31 price target. The shares currently do not reflect the overall opportunity for tipifarnib, which is about to enter a pivotal program in head and neck squamous cell carcinoma patients as well as several other indications, which could lead to a broad label for the drug, Pantginis tells investors in a research note.
07/09/18
OPCO
07/09/18
NO CHANGE
Target $35
OPCO
Outperform
Kura Oncology price target raised to $35 from $27 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Kura Oncology to $35 from $27, citing an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$367.70

0.94 (0.26%)

10:04
12/13/18
12/13
10:04
12/13/18
10:04
On The Fly
Analyst sees narrative around Tesla changing as Wired reports on 'rage firings' »

Shares of Tesla (TSLA)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MGLN

Magellan Health

$61.38

2.75 (4.69%)

10:03
12/13/18
12/13
10:03
12/13/18
10:03
Hot Stocks
Magellan rallies after activist Starboard discloses nearly 10% stake »

Jeff Smith's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$20.67

-0.57 (-2.68%)

10:01
12/13/18
12/13
10:01
12/13/18
10:01
Upgrade
TechnipFMC rating change  »

BMO Capital says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PYPL

PayPal

$88.01

1.51 (1.75%)

10:01
12/13/18
12/13
10:01
12/13/18
10:01
Conference/Events
PayPal management to meet with Wedbush »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

  • 13

    Dec

  • 18

    Dec

OXM

Oxford Industries

$67.67

-7.21 (-9.63%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Oxford Industries falls -9.0% »

Oxford Industries is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$58.45

-6.2 (-9.59%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN falls -9.8% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$14.56

-5.6 (-27.78%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Tailored Brands falls -27.5% »

Tailored Brands is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$5.99

0.73 (13.88%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Qudian rises 13.9% »

Qudian is up 13.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAC

Macerich

$48.91

1.78 (3.78%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Options
Call buyers in Macerich as shares gain 3% »

Call buyers in Macerich…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$35.52

3.385 (10.53%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Ciena rises 11.5% »

Ciena is up 11.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

VNCE

Vince Holding

$9.92

(0.00%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Vince Holding rises 16.1% »

Vince Holding is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

XPO

XPO Logistics

$59.58

-0.67 (-1.11%)

09:55
12/13/18
12/13
09:55
12/13/18
09:55
Options
XPO Logistics put volume heavy and directionally bearish »

Bearish flow noted in XPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$7.37

0.65 (9.67%)

, AFL

Aflac

$45.33

2.44 (5.69%)

09:55
12/13/18
12/13
09:55
12/13/18
09:55
Options
Early notable gainers among liquid option names on December 13th »

Notable gainers among…

GE

General Electric

$7.37

0.65 (9.67%)

AFL

Aflac

$45.33

2.44 (5.69%)

MAC

Macerich

$48.39

1.26 (2.67%)

KMB

Kimberly-Clark

$115.99

2.12 (1.86%)

FSLR

First Solar

$44.40

0.8 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

HIIQ

Health Insurance Innovations

$30.02

-0.045 (-0.15%)

09:55
12/13/18
12/13
09:55
12/13/18
09:55
Conference/Events
Health Insurance Innovations to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

XPO

XPO Logistics

$59.87

-0.385 (-0.64%)

09:53
12/13/18
12/13
09:53
12/13/18
09:53
Hot Stocks
Spruce Point calls XPO financials 'dubious,' sees up to 100% downside risk »

Short seller Spruce Point…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:50
12/13/18
12/13
09:50
12/13/18
09:50
General news
Treasury 30-year auction outlook: »

Treasury 30-year auction…

ARMK

Aramark

$32.76

0.65 (2.02%)

09:50
12/13/18
12/13
09:50
12/13/18
09:50
Recommendations
Aramark analyst commentary  »

Aramark price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$58.95

-1.3 (-2.16%)

09:48
12/13/18
12/13
09:48
12/13/18
09:48
Periodicals
Spruce Point names XPO Logistics a 'Strong Sell,' sees '100% long-term downside' »

Spruce Point Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNT

Unit Corp.

$18.33

-0.755 (-3.96%)

09:47
12/13/18
12/13
09:47
12/13/18
09:47
Hot Stocks
Unit Corp. falls -5.2% »

Unit Corp. is down -5.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$57.49

-7.16 (-11.08%)

09:47
12/13/18
12/13
09:47
12/13/18
09:47
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN falls -11.3% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$14.73

-5.43 (-26.93%)

09:47
12/13/18
12/13
09:47
12/13/18
09:47
Hot Stocks
Tailored Brands falls -26.8% »

Tailored Brands is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$130.50

13.6 (11.63%)

09:47
12/13/18
12/13
09:47
12/13/18
09:47
Hot Stocks
VelocityShares 3x Long Natural Gas ETN rises 11.5% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$36.00

3.865 (12.03%)

09:47
12/13/18
12/13
09:47
12/13/18
09:47
Hot Stocks
Ciena rises 13.0% »

Ciena is up 13.0%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

QD

Qudian

$6.22

0.96 (18.25%)

09:47
12/13/18
12/13
09:47
12/13/18
09:47
Hot Stocks
Qudian rises 18.3% »

Qudian is up 18.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$20.97

-0.27 (-1.27%)

09:46
12/13/18
12/13
09:46
12/13/18
09:46
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.